Sangamo Therapeutics, Inc.
NEWS
Sangamo Therapeutics announced positive preliminary findings from its ongoing Phase I/II STAAR clinical trial in Fabry disease.
Biopharma companies recognized that developing a therapy is merely the beginning of what is needed to connect patients with sickle cell disease to next-level therapies.
Mammoth will use the funds to build and broaden its stable of next-generation CRISPR products to detect and cure various diseases.
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here’s a look at a few of the bay area biotech companies hiring now.
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry.
The Brisbane, California-based company announced its plans to separate the two units and treat them as individual operations with individual managers.
Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.
Biopharma and life sciences companies bolster their leadership teams and boards with this week’s Movers & Shakers.
Biogen and Sangamo Therapeutics announced a broad global licensing collaboration deal to develop and commercialize several compounds for a range of neurological and neuromuscular diseases.
JOBS
IN THE PRESS